Anti-body Coupled T Receptor Therapy Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis

 

Anti-body coupled T receptor (ACTR) therapy is sort of immunotherapy used to treat cancer by which body's own immune response is utilized to do something on cancerous cell. Anti-body coupled T receptor therapy utilizes T cells from body, engineered it to express specific T cell receptor, multiplying it in lab and then administering it along side targeting antibodies. The benefit in this process is, why these T cells do not attack normal antigens from blood circulation but attack only antigens attached with the cancerous cells. That is possible as tumor specific monoclonal antibodies are shown along with ACTR T cells. ACTR therapy is cost effective because it can be utilized in several cancer therapy. Also, greater therapeutic benefit with minimum negative effects can be possible by adjusting the amount of targeting antibody that will be essential for activation of the ACTR T cells.

ACTR therapy is much better in its approach than other adoptive T cell transfer technologies such as for instance CAR-T cell therapy. CAR-T therapy products such as for instance Kymriah (Novartis AG) or Yescarta (Gilead Lifescience, Inc.) has negative effects such as for instance cytokine release syndrome, and neurological toxicity as discussed in their respective product literatures and other studies. ACTR therapy being specific in its action do not produce such side effects. This advantage would drive the Anti-body Coupled T Receptor Therapy Market in future. Also CAR-T therapy has application in specific kind of cancer such as for instance non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma whereas ACTR therapy has potential use even yet in solid tumorous cancer such as for instance breast cancer, and neuroblastoma.